Deciphera Pharmaceuticalsincis A Biopharmaceutical Company Based In Walthammassachusettsfocused On Discovering And Developing Innovative Medicinesparticularly Kinase Inhibitors For Various Diseasesincluding Cancerfounded In 2003The Company Became A Member Of Ono Pharma Following An Acquisition In June 2024 The Company Utilizes Its Proprietary Switch Control Inhibitor Platform To Design And Develop Kinase Inhibitorsdeciphera Collaborates With Academic Institutionsresearch Organizationsand Pharmaceutical Companies To Enhance The Development And Commercialization Of Its Therapiesits Product Pipeline Includes Ripretinib For Gastrointestinal Stromal Tumorsvimseltinibromvimzafor Tenosynovial Giant Cell Tumorand Several Other Candidates In Development For Conditions Such As Renal And Colon Cancersautoimmune Diseasesand Solid Tumorsdeciphera S Mission Is To Improve The Lives Of Patients By Providing Effective Treatments For Cancer And Other Serious Conditions
